Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hydatidiform mole associated and imprinted (HYMAI) is a long non-coding RNA (lncRNA) gene, paternally expressed and located within the 6q24 chromosomal domain. HYMAI is notable for its epigenetic regulation through genomic imprinting—it is differentially methylated and expressed only from the paternal allele. Overexpression of HYMAI, often occurring alongside the protein-coding gene PLAG1/PLAGL1 (ZAC), is strongly linked to transient neonatal diabetes mellitus (TNDM), a rare disorder causing impaired insulin secretion and significant growth failure in newborns. HYMAI’s precise molecular function remains incompletely characterized, but it likely contributes to chromatin structure, gene expression regulation, and cellular developmental processes in pancreatic endocrine cells. There are no known drugs that directly target HYMAI, and it is not considered a therapeutic target such as a receptor or enzyme, but serves as an important molecule in the study of imprinting disorders and epigenetic regulation[5][7][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hydatidiform mole associated and imprinted (non-protein coding) (HYMAI).